Drug Profile
Research programme: anti-CD20 monoclonal antibody - AstraZeneca
Alternative Names: Anti-CD20 mAB - AstraZeneca ; B cell depletion therapy - AstraZenecaLatest Information Update: 09 Aug 2021
Price :
$50
*
At a glance
- Originator MedImmune
- Developer AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action CD20 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Autoimmune-disorders in USA (Parenteral)